mosquitoborn
chikungunya
viru
chikv
caus
chikungunya
fever
clinic
present
sever
back
small
joint
pain
debilit
arthriti
associ
crippl
pain
persist
week
even
year
although
sever
studi
evalu
efficaci
drug
chikv
treatment
chikungunya
fever
mainli
symptombas
effect
licens
vaccin
antivir
avail
investig
antivir
activ
three
type
flavonoid
chikv
vitro
replic
three
compound
silymarin
quercetin
kaempferol
evalu
vitro
antivir
activ
chikv
use
chikv
replicon
cell
line
clinic
isol
chikv
centraleast
african
genotyp
cytopath
effect
inhibit
assay
use
determin
activ
chikv
viral
replic
quantit
revers
transcript
pcr
use
calcul
viru
yield
antivir
activ
effect
compound
investig
evalu
chikv
protein
express
use
western
blot
chikv
protein
briefli
silymarin
exhibit
signific
antivir
activ
chikv
reduc
chikv
replic
effici
downregul
product
viral
protein
involv
replic
studi
may
import
consequ
broaden
chanc
get
effect
antivir
chikv
infect
phylogenet
analysi
show
chikv
three
genotyp
variant
west
african
eastcentr
south
african
ecsa
asian
malaysia
first
outbreak
late
suburb
klang
state
selangor
chikv
identifi
asian
genotyp
local
outbreak
cluster
case
report
larut
matang
lama
perak
ecsa
genotyp
viru
caus
outbreak
earli
togeth
neighbor
singapor
epidem
johor
began
spread
throughout
state
peninsular
malaysia
mani
case
occur
selangor
melaka
negeri
sembilan
pahang
state
peak
kelantan
kedah
terengganu
perli
sarawak
april
march
case
report
nationwid
outbreak
although
fatal
main
mosquito
vector
chikv
aegypti
albopictu
aegypti
primari
vector
outbreak
happen
kenya
comoro
africa
asia
asian
tiger
mosquito
albopictu
main
vector
reunion
subsequ
indian
ocean
outbreak
vector
switch
albopictu
becam
predomin
due
substitut
alanin
residu
valin
residu
chikv
protein
converg
mutat
seem
due
select
pressur
impact
differ
new
environ
ecosystem
extens
studi
continu
around
world
find
effect
cure
safe
antivir
treatment
vaccin
chikv
infect
one
studi
shown
chloroquin
phosphat
antimalari
drug
decreas
intens
durat
pain
number
joint
involv
howev
effect
chloroquin
treat
chronic
symptom
could
evalu
due
lack
adequ
control
patient
symptom
synergist
effect
ribavirin
interferon
alpha
chikv
infect
report
vitro
studi
shown
arbidol
strongli
interfer
earli
stage
chikv
infect
target
cellular
membran
howev
potent
inhibitor
vitro
chikv
infect
flavonoid
polyphenol
compound
present
differ
plant
food
drink
flavonoid
well
known
differ
biolog
properti
includ
antimicrobi
activ
antiinflammatori
activ
antiallerg
activ
cytotox
antitumor
activ
quercetin
antivir
activ
herp
simplex
viru
hsv
respiratori
syncyti
viru
pseudorabi
viru
parainfluenza
viru
type
sindbi
viru
type
member
genu
alphaviru
mechan
action
quercetin
includ
enhanc
antivir
activ
interferon
bind
viral
protein
interf
viral
nucleic
acid
synthesi
bind
viral
polymeras
anoth
flavonoid
kaempferol
activ
hsv
human
coronaviru
rotaviru
replic
silymarin
extract
milk
thistl
silybum
marianum
shown
inhibit
hepat
c
viru
hcv
vitro
vivo
inhibit
hcv
entri
rna
synthesi
viral
protein
express
infecti
viru
product
addit
also
act
block
viru
celltocel
spread
becom
concern
explain
definit
nomenclatur
milk
thistl
extract
silymarin
silibinin
sinc
find
discuss
involv
three
import
term
brief
initi
extract
crush
milk
thistl
seed
made
silymarin
fatti
acid
linol
acid
silymarin
complex
flavonolignan
silybin
silybin
b
isosilybin
isosilybin
b
silychristin
isosilychristin
silydianin
flavonoid
wherea
silibinin
semipurifi
commerci
avail
fraction
silymarin
approxim
mixtur
diastereoisomer
compound
silybin
silybin
b
also
refer
literatur
silibinin
b
evalu
vitro
antivir
activ
quercetin
kaempferol
silymarin
clinic
isol
chikv
result
support
antivir
properti
silymarin
promis
compound
investig
toward
develop
antichikv
drug
cytotox
flavonoid
mt
assay
use
determin
cytotox
flavonoid
vero
bhk
cell
cc
valu
compound
calcul
tabl
observ
antivir
activ
assay
primari
screen
differ
noncytotox
concentr
silymarin
kaempferol
quercetin
test
chikvinfect
vero
cell
find
effect
compound
cpe
inhibit
assay
use
hpi
shown
gml
silymarin
significantli
inhibit
chikvcp
present
p
fig
find
unexpect
silybin
also
known
silibinin
one
compon
silymarin
shown
possess
antichikv
activ
contrast
highest
concentr
quercetin
kaempferol
exhibit
cpe
inhibitori
activ
fig
result
cpe
inhibit
assay
confirm
use
mt
assay
fig
silymarin
inhibit
earli
postentri
stage
chikv
replic
analyz
compound
silymarin
abl
suppress
chikv
mediat
cytotox
therefor
chosen
timeofaddit
assay
perform
aim
determin
stage
viru
infect
cycl
compound
affect
shown
fig
inhibit
effici
silymarin
ad
hpi
timedepend
inhibitori
effect
compound
coher
hypothesi
antichikv
activ
may
due
inhibit
earli
probabl
postentri
step
chikv
replic
cycl
antientri
assay
also
perform
result
clearli
shown
antivir
activ
silymarin
chikv
antientri
phase
fig
cell
line
contain
noncytotox
replicon
chikv
addit
viru
replicas
protein
express
also
puromycin
acetyl
transferas
egfp
rluc
marker
system
rluc
activ
proport
viral
replicon
rna
replic
found
gml
silymarin
suppress
activ
rluc
marker
express
chikv
replicon
fig
inhibit
highli
signific
p
confirm
silymarin
affect
postentri
step
chikv
infect
data
also
indic
silymarin
interfer
chikv
rna
replic
affect
viral
replicas
system
interestingli
previou
studi
ic
silybin
one
major
compon
silymarin
estim
approxim
gml
compar
silymarin
somewhat
effici
nearli
threefold
inhibit
observ
gml
indic
compon
silymarin
like
contribut
antichikv
activ
confirm
postentri
antivir
activ
silymarin
chikv
viru
yield
assay
use
qrtpcr
use
chikv
rna
copi
number
supernat
cell
treat
concentr
inhibitor
control
cell
interpret
depict
fig
signific
reduct
chikv
replic
treat
increas
concentr
silymarin
p
silymarin
exhibit
statist
signific
p
dosedepend
inhibit
rluc
activ
produc
bhkchikvnct
replicon
rluc
activ
measur
h
post
treatment
vehicletr
dmso
cell
use
control
concentr
data
triplic
assay
plot
analyz
nonparametr
correl
spearman
twotail
test
graph
pad
prism
version
graph
pad
softwar
inc
san
diego
ca
compar
vehicl
control
treat
cell
base
data
calcul
silymarin
ic
gml
select
index
si
take
account
ad
silymarin
hpi
show
signific
inhibitori
effect
chikv
replic
confirm
silymarin
act
postentri
stage
chikv
infect
contrast
similar
assay
neither
kaempferol
quercetin
show
signific
inhibitori
effect
chikv
replic
fig
shown
fig
gml
silymarin
inhibit
chikv
yield
evalu
whether
silymarin
also
affect
chikv
protein
synthesi
seri
western
blot
analys
perform
use
lysat
chikv
infect
silymarin
treat
vero
cell
fig
evid
constant
level
actin
silymarin
treatment
result
protein
degrad
use
concentr
compound
toxic
vero
cell
contrast
dosedepend
reduct
amount
protein
observ
fig
indic
silymarin
limit
chikv
replic
virusencod
protein
synthesi
within
treat
cell
silybin
interfer
earli
postentri
chikv
infect
dosedepend
manner
question
whether
silymarin
effect
chikv
replic
influenc
fraction
made
sinc
studi
done
pohjala
l
et
al
prove
silybin
one
silymarin
fraction
suppress
activ
rluc
marker
gene
express
chikv
replicon
evalu
effect
silybin
chikv
intracellular
replic
henc
silybin
test
earli
postentri
activ
confirm
antichikv
activ
dosedepend
manner
ic
higher
ic
silymarin
result
make
us
conclud
activ
silymarin
chikv
replic
might
also
enhanc
compon
fraction
made
consid
crippl
pain
persist
week
even
year
due
chikv
infect
absenc
antivir
treatment
viru
search
effect
antivir
compound
imper
due
known
broad
spectrum
antivir
activ
low
toxic
evalu
three
flavonoid
viabl
candid
compound
compound
silymarin
identifi
flavonoid
signific
antichikv
activ
consid
potenti
futur
develop
use
result
reduct
chikv
infect
base
cpe
inhibit
mt
assay
fig
remark
effect
concentr
silymarin
much
lower
mntd
contrast
neither
kaempferol
quercetin
show
signific
antivir
activ
vitro
replic
chikv
assay
quantifi
copi
number
viral
rna
releas
probabl
form
genom
rna
pack
virion
infect
cell
use
qrtpcr
amplifi
part
encod
region
chikv
genom
sinc
involv
negativestrand
subgenom
rna
synthesi
quantif
negativestrand
rna
reflect
activ
viral
replic
select
gene
target
qrtpcr
quantifi
viru
load
replic
data
demonstr
treatment
silymarin
result
effect
reduct
number
releas
viral
genom
indic
reduct
viral
rna
synthesi
andor
virion
format
releas
postadsorpt
assay
silymarin
taken
gml
result
inhibit
chikv
replic
therefor
perform
timeofaddit
assay
use
concentr
silymarin
determin
stage
infect
silymarin
treatment
result
biggest
antivir
effect
result
consist
data
postadsorpt
assay
henc
conclud
silymarin
effect
ad
shortli
viru
infect
hpi
reason
lower
antichikv
activ
pretreat
silymarin
could
due
halflif
silymarin
base
previou
bioavail
studi
less
hour
although
data
avail
vitro
halflif
stabil
silymarin
might
interest
futur
studi
find
consist
hypothesi
silymarin
effect
postentri
stage
chikv
dose
respons
analysi
also
perform
use
chikv
replicon
cell
line
viru
entri
exit
take
place
found
silymarin
abl
suppress
activ
rluc
marker
express
chikv
replicon
find
consist
previou
assay
confirm
silymarin
suppress
chikv
rna
replic
dosedepend
manner
rluc
express
chikv
replicon
fuse
protein
viru
accordingli
reduct
rluc
activ
indic
reduc
amount
protein
chikv
replicon
cell
line
confirm
antichikv
activ
silymarin
shown
effect
silymarin
viral
protein
synthesi
chikv
infect
cell
fig
decreas
viral
protein
synthesi
observ
effect
could
due
inhibit
chikv
rna
replic
andor
transcript
howev
viru
express
replicon
cell
line
synthesi
viral
rna
protein
coupl
studi
necessari
evalu
direct
effect
silymarin
inhibit
newli
synthes
chikv
protein
possibl
nonstructur
protein
chikv
repres
direct
target
silymarin
possibl
includ
protein
involv
synthesi
neg
strand
viral
rna
rna
cap
protein
anoth
compon
viral
replicas
complex
regul
express
may
repres
consequ
suppress
replic
directli
via
inhibit
nsprotein
howev
regul
clearli
relev
point
view
develop
effect
antivir
protein
one
import
virion
glycoprotein
essenti
receptor
bind
interestingli
previou
studi
show
silymarin
inhibit
express
hepat
c
viru
hcv
catalyt
subunit
hcv
replicas
although
hepatoprotect
properti
silymarin
context
block
hcv
infect
base
vivo
studi
anoth
import
criteria
compound
consid
therapeut
candid
hepat
c
studi
repres
import
first
report
antichikv
properti
silymarin
previous
flavonoid
apigenin
chrysin
naringenin
silybin
also
one
compon
silymarin
known
inhibitor
viral
replic
mainli
affect
import
cellular
element
chikv
replic
howev
inhibitori
properti
silymarin
somewhat
differ
silybin
thu
data
silymarin
warrant
mechanist
studi
character
antivir
properti
compon
flavonoid
compound
headtohead
comparison
antivir
effect
lower
concentr
differ
condit
best
option
antichikv
determin
summari
studi
show
silymarin
exhibit
signific
vitro
antivir
activ
chikv
suppress
postentri
stage
viral
replic
like
chikv
rna
replic
significantli
dose
depend
manner
coher
express
protein
need
rna
replic
also
express
viral
structur
protein
downregul
contrast
silymarin
found
quercetin
kaempferol
unabl
suppress
chikv
replic
accordingli
good
candid
antichikv
drug
find
warrant
futur
mechanist
vivo
antivir
toxic
pharmacokinet
studi
part
process
evalu
silymarin
potenti
antichikv
therapeut
viru
cell
chikv
isol
use
experi
clinic
isol
outbreak
johor
code
belong
ecsa
genotyp
mutat
protein
babi
hamster
kidney
vero
african
green
monkey
kidney
cell
american
type
cultur
collect
atcc
use
studi
vero
cell
wide
use
vitro
antivir
research
exampl
antivir
test
chikungunya
viru
human
enteroviru
coxsackieviru
cell
line
cultur
use
eagl
minimum
essenti
medium
emem
gibco
ny
usa
contain
inactiv
fetal
bovin
serum
fb
penicillinstreptomycin
incub
co
chikv
strain
propag
cell
harvest
full
cytopath
effect
cpe
observ
viru
stock
titer
determin
tissu
cultur
infecti
dose
tcid
method
obtain
stock
aliquot
store
time
viru
propag
antivir
assay
fb
concentr
cell
cultur
medium
reduc
vero
cell
line
use
experi
mt
assay
antivir
assay
chikv
replicon
cell
grown
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
ny
usa
supplement
fetal
bovin
serum
fb
tryptosebroth
phosphat
penicillinstreptomycin
incub
co
flavonoid
silymarin
quercetin
kaempferol
purchas
sigmaaldrich
corpor
sigmaaldrich
st
loui
mo
usa
store
futur
use
stock
solut
dilut
emem
filter
syring
filter
pore
size
millipor
usa
time
use
dmso
concentr
work
solut
prepar
emem
kept
assay
promega
wi
usa
perform
evalu
cytotox
test
compound
vero
cell
cell
accord
manufactur
protocol
briefli
monolay
vero
cell
grown
plate
treat
differ
concentr
compound
triplic
togeth
neg
control
media
contain
dmso
plate
incub
co
hour
mt
assay
perform
treat
control
cell
kept
two
day
similar
condit
durat
use
antivir
activ
assay
two
day
posttreat
mt
solut
ad
cell
incub
hour
co
prior
absorb
detect
nm
wavelength
use
infinit
pro
multipl
reader
tecan
switzerland
experi
conduct
triplic
half
maxim
cytotox
concentr
cc
compound
determin
assay
use
graph
pad
prism
graph
pad
softwar
inc
san
diego
ca
usa
antivir
activ
assay
primari
assay
antivir
activ
monolay
vero
cell
grown
plate
emem
contain
inactiv
fb
test
compound
ad
well
triplic
togeth
chikv
moi
plate
incub
co
hour
assay
conduct
duplic
concentr
compound
two
day
plate
view
microscop
degre
cytopath
effect
cpe
measur
viru
replic
inhibit
express
percent
yield
viru
control
viru
control
cpe
experiment
groupcp
viru
control
result
confirm
perform
mt
assay
promega
wi
usa
accord
manufactur
protocol
experi
repeat
three
time
independ
statist
analysi
percentag
cpe
inhibit
perform
use
gaussian
popul
pearson
twotail
assay
antientri
assay
procedur
antientri
assay
modifi
perform
accord
lee
rch
et
al
monolay
vero
cell
grown
plate
emem
supplement
inactiv
fb
vero
cell
infect
chikv
plate
incub
hour
nonadsorb
viru
wash
test
compound
ad
differ
concentr
incub
co
hour
plate
wash
treat
citrat
buffer
ph
inactiv
nonintern
viru
plate
wash
emem
supplement
inactiv
fb
ad
everi
well
plate
incub
hour
co
chikv
replicon
cell
line
base
assay
monolay
chikv
replicon
cell
prepar
white
plate
corn
inc
ny
usa
treat
differ
concentr
test
compound
hour
incub
co
activ
renilla
luciferas
rluc
express
chikv
replicon
detect
use
renilla
luciferas
assay
promega
wi
usa
perform
accord
manufactur
protocol
luminesc
signal
measur
use
glomax
luminomet
promega
wi
usa
plot
log
transform
concentr
compound
sigmoid
curv
fit
variabl
slope
creat
obtain
half
maxim
inhibitori
concentr
ic
valu
compound
graph
pad
prism
graph
pad
softwar
inc
san
diego
ca
usa
data
repres
mean
standard
error
mean
sem
triplic
assay
three
independ
experi
statist
analysi
determin
correl
concentr
silymarin
rluc
activ
perform
use
nonparametr
correl
spearman
twotail
assay
timeofaddit
assay
experi
monolay
vero
cell
grown
plate
emem
contain
inactiv
fb
well
triplic
design
name
accord
time
chikv
moi
infect
hour
vero
cell
treat
gml
silymarin
plate
incub
one
hour
co
one
hour
later
hour
well
also
treat
gml
silymarin
hour
well
except
control
well
infect
chikv
incub
one
hour
co
incub
everi
incub
co
gml
silymarin
ad
hour
well
respect
plate
incub
co
hour
supernat
treat
control
well
treat
dmso
use
vehicl
control
collect
two
day
posttreat
analyz
use
qrtpcr
half
maxim
effect
concentr
ec
silymarin
calcul
use
graph
pad
prism
graph
pad
softwar
inc
san
diego
ca
usa
data
triplic
assay
three
independ
experi
quantit
revers
transcript
pcr
qrtpcr
qrtpcr
assay
use
quantifi
chikv
rna
copi
number
amplif
base
region
encod
sequenc
perform
describ
chiam
colleagu
primer
cdna
first
gener
rna
extract
supernat
qiagen
germani
previou
assay
plate
use
primer
superscript
iii
revers
transcriptas
life
technolog
usa
accord
manufactur
protocol
unincorpor
primer
digest
exonucleas
new
england
biolab
usa
qrtpcr
perform
steponeplu
realtim
pcr
system
life
technolog
usa
power
sybrgreen
pcr
master
mix
life
technolog
usa
follow
manufactur
protocol
use
serial
dilut
standard
cycl
paramet
min
cycl
min
amplifi
product
verifi
melt
curv
analysi
statist
analysi
determin
correl
rna
copi
number
silymarin
concentr
perform
use
gaussian
popul
pearson
twotail
assay
western
blot
vero
cell
densiti
cell
seed
cm
flask
emem
contain
fb
penicillinstreptomycin
next
day
flask
infect
chikv
inoculum
moi
place
rocker
minut
incub
co
h
flask
treat
differ
concentr
gml
trial
compound
control
flask
treat
solut
contain
dmso
flask
incub
co
appear
cpe
vehicl
control
cpe
observ
cell
scrape
wash
pb
lyse
use
l
triton
sigmaaldrich
st
loui
mo
usa
contain
complet
proteas
inhibitor
cocktail
sigmaaldrich
st
loui
mo
usa
min
cellular
debri
pellet
centrifug
g
min
micro
bca
tm
protein
assay
kit
thermo
scientif
rockford
il
use
quantifi
protein
concentr
sampl
lysat
contain
g
protein
denatur
use
sdsload
buffer
protein
separ
use
sdspage
gel
gel
equilibr
towbin
buffer
tri
glycin
methanol
min
protein
transfer
pvdf
membran
use
biorad
wet
transfer
system
bio
rad
san
francisco
ca
detect
membran
block
pb
casein
blocker
bio
rad
san
francisco
ca
h
room
temperatur
shaker
blot
rins
three
time
pb
incub
primari
antichikv
antichikv
antichikv
rabbit
polyclon
antibodi
casein
solut
blot
wash
three
time
pb
min
time
follow
incub
secondari
goat
antirabbit
igg
abcam
cambridg
uk
antibodi
conjug
horseradish
peroxidas
hrp
h
room
temperatur
orbit
shaker
membran
wash
three
time
pb
contain
tween
minut
time
load
control
separ
blot
contain
sampl
incub
primari
mous
monoclon
antibodi
conjug
hrp
cell
signal
technolog
usa
dissolv
casein
hour
room
temperatur
shaker
blot
wash
three
time
pb
tween
minut
time
membran
develop
colorimetr
method
use
appropri
substrat
thermo
scientif
rockford
il
